可切除非小细胞肺癌的辅助免疫疗法:目前的进展和未来的前景
Alice Ravasin1, Lavinia Gatteschi1, Valentina Massa2
1Thoracic Surgery Unit, Careggi University Hospital, 50134 Florence, Italy.
Cancers
|July 12, 2025
概括
免疫检查点抑制剂 (ICI) 显著改善了手术后可切除非小细胞肺癌 (NSCLC) 的无病生存率. 目前正在进行的研究重点是优化患者选择和治疗持续时间,以获得更好的长期结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 可切除非小细胞肺癌 (NSCLC) 的辅助治疗随着免疫检查点抑制剂 (ICI) 的出现而发展.
- ICI增强宿主免疫系统以向癌细胞,改善各种恶性瘤的结果.
- 最近的临床试验强调了ICI在NSCLC的辅助环境中的有效性.
研究的目的:
- 审查目前关于ICI在可切除NSCLC的辅助治疗中的疗效和安全性的证据.
- 讨论生物标志物的作用,如编程死亡-连接体1 (PD-L1),在患者选择.
- 探索正在进行的研究,以优化治疗持续时间和组合疗法.
主要方法:
- 关键临床试验的审查,包括IMpower010 (阿特索利祖马布) 和PEARLS/KEYNOTE-091 (佩姆罗利祖马布).
- 基于PD-L1表达和疾病阶段的无病生存期 (DFS) 数据的分析.
- 评估与ICI相关的安全概况和与免疫相关的不良事件.
主要成果:
- 辅助性ICI在不同阶段和PD-L1表达水平的可切除NSCLC的DFS中显示出显著的改善.
- 阿特佐利祖马布在II-IIIANSCLC的II-IIIA阶段,PD-L1表达≥1% (HR 0.66) 和整体人群 (HR 0.79) 中显示了DFS益处.
- 与安慰剂相比, pembrolizumab 在IB-IIIA期NSCLC中改善了DFS,DFS的中位数为53.6个月,而42.0个月.
结论:
- ICI代表了可切除NSCLC的辅助疗法的重大进展,改善了DFS.
- 需要进一步的研究,通过生物标志物来完善患者选择,并优化治疗策略.
- 仔细监测与免疫相关的不良事件至关重要,特别是在组合疗法中.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.2K
相关概念视频
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Vaccines
517
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
517
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
